

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

JUNE 12, 2000

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS

On June 12, 2000, Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-) announced that the Company can now support clinical trials in Latin America with routine safety testing through the Company's standardized laboratory in Miami. In addition, Latin American investigators will have access to LabCorp's full menu of more than 2,500 tests, including many advanced esoteric assays, through its network of other testing facilities.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS

- (c) Exhibit
20 Press release of the Company dated
June 12, 2000.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By: /s/BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer

Date: June 21, 2000

Laboratory Corporation of America-Registered Trademark- Holdings
358 South Main Street
Burlington, NC 27215
Telephone: 336-584-5171

FOR IMMEDIATE RELEASE

Contact: 336-436-4855
Pamela Sherry

Shareholder Direct: 800-LAB-0401
www.labcorp.com

LABCORP TO PROVIDE CENTRALIZED LABORATORY SERVICES FOR
CLINICAL TRIALS IN LATIN AMERICA

BURLINGTON, N.C., June 12, 2000 - The clinical trials testing division of Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-Registered Trademark-; NYSE: LH) can now support clinical trials in Latin America with routine safety testing through the company's standardized laboratory in Miami. In addition, Latin American investigators will have access to LabCorp's full menu of more than 2,500 tests, including many advanced esoteric assays, through its network of other testing facilities.

"Latin America is the world's third most active region for clinical trials after the U.S. and Europe," said Scott Neilson, vice president and general manager of LabCorp's clinical trials business. "This move enables us to bring our extensive capabilities to our customers' drug development efforts in Latin America and centralize laboratory testing throughout the region. By using LabCorp's facilities in Florida, we can provide enormous capacity while ensuring compliance with regulatory standards and maintaining method consistency and data combinability which are critically important to our customers."

Sue Hwang, LabCorp's director of operations for clinical trials, added, "Sample transit time, costs and Customs issues have made it difficult for central laboratories to support clinical trials in Latin America. LabCorp's extensive operations in Miami, a transportation hub serving Latin America, allow us to accession samples even more quickly and economically than if they had to be routed to a laboratory in Latin America. Because of existing courier routes and logistics issues, samples traveling between Latin American countries typically go through U.S. Customs in Miami. By testing samples in Miami, LabCorp can lower not only study budgets but also the risks associated with multiple flight segments."

LabCorp projects that infectious disease testing, including HIV phenotyping/genotyping, will initially account for most of its Latin America clinical trials volume. The region has the world's fourth-highest incidence of HIV/AIDS.

With U.S. headquarters in Raritan, N.J., and European headquarters in Mechelen, Belgium, LabCorp's clinical trials division is a leading central laboratory supporting global pharmaceutical, biotechnology, and medical device clinical trials with method development and a broad menu of safety and efficacy testing from drug discovery through phase IV.

With headquarters in Burlington, N.C., Laboratory Corporation of America-Registered Trademark- Holdings is a national clinical laboratory organization, which operates facilities for conducting clinical assays and diagnostic testing throughout the U.S. The company had 1999 revenues of \$1.7 billion and employs approximately 18,000.

The Company noted that each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 1999 and subsequent SEC filings.

For further information, business/financial reporters should contact Pam Sherry, Laboratory Corporation of America-Registered Trademark- Holdings, 358 South Main Street, Burlington, NC 27215, phone: 336-436-4855, e-mail: sherry@labcorp.com. Trade journal reporters should contact Amy Smith, Worldwide Marketing Manager, Clinical Trials, LabCorp, 69 First Avenue, Raritan, NJ 08869; phone: 908-526-2400, e-mail: smitha@labcorp.com.

###